Quarterly ResultMay 13, 2026, 07:13 AM
Milestone Pharma CARDAMYST Launch Gains Traction; AFib-RVR Phase 3 Initiated
AI Summary
Milestone Pharmaceuticals Inc. reported its first quarter 2026 financial results, highlighting positive traction for its CARDAMYST™ (etripamil) nasal spray launch for PSVT. The company secured national formulary coverage with Express Scripts, making CARDAMYST accessible to over 25% of commercially insured lives. Additionally, Milestone initiated a Phase 3 registration trial for etripamil in Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR), with patient enrollment expected in the second half of 2026. The company maintains a strong balance sheet with $184.2 million in cash, providing a runway into H2 2027.
Key Highlights
- CARDAMYST launch initiated mid-February 2026, with approximately 600 scripts filled for 560 patients.
- Approximately 400 unique prescribers have started patients on CARDAMYST.
- Express Scripts national formulary coverage secured, covering over 25% of commercially insured lives.
- Phase 3 registrational program for etripamil in AFib-RVR initiated, with patient enrollment expected H2 2026.
- Cash, cash equivalents, and short-term investments totaled $184.2 million as of March 31, 2026.
- Product revenues were $0.2 million for Q1 2026, up from $0 in Q1 2025.
- Net loss for Q1 2026 was $26.1 million, or $0.20 per share, compared to $20.8 million, or $0.31 per share in Q1 2025.
- Commercial expense increased to $15.8 million in Q1 2026 from $10.4 million in Q1 2025 due to CARDAMYST launch.
Price Impact
More from MIST